Experienced in Systemic Lupus Erythematosus (SLE)

Milan S. Petronijevic

Belgrade, SE, RS 
Experienced in Systemic Lupus Erythematosus (SLE)
Belgrade, SE, RS 
OverviewLocationsClinical Research

Overview

Milan Petronijevic practices in Belgrade, Serbia. Petronijevic is rated as an Experienced expert by MediFind in the treatment of Systemic Lupus Erythematosus (SLE). Their top areas of expertise are Systemic Lupus Erythematosus (SLE), Arthritis, and Rheumatoid Arthritis (RA).

Their clinical research consists of co-authoring 19 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles and participated in 3 clinical trials in the study of Systemic Lupus Erythematosus (SLE).

Locations

Belgrade, SE, Serbia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

19 Total Publications

Dermatomyositis as the First Manifestation of Nasopharyngeal Carcinoma-A Rare Case Report.
Dermatomyositis as the First Manifestation of Nasopharyngeal Carcinoma-A Rare Case Report.
Journal: Medicina (Kaunas, Lithuania)
Published: January 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Petronijevic's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile